论文部分内容阅读
目的观察肿瘤干细胞标志物CD133和CD147在非小细胞肺癌(NSCLC)组织中的表达及其临床意义。方法用免疫组织化学方法检测77例NSCLC组织中CD133与CD147的表达,分析其与患者肿瘤大小、组织学类型、组织分化程度、淋巴结转移和预后的关系。结果77例NSCLC组织中CD133与CD147的阳性表达率分别为51.9%(40/77)和67.5%(52/77)。CD133和CD147的表达与淋巴结转移呈正相关(r=0.246,P<0.05;r=0.295,P<0.05);CD133和CD147的表达均与患者术后生存时间呈负相关(P<0.05)。CD133和CD147的表达与肿瘤大小、组织学类型和组织分化程度均无明显相关(P>0.05)。CD133与CD147的表达之间呈正相关(r=0.315,P<0.05)。结论肿瘤干细胞标志物CD133和CD147的表达与NSCLC的淋巴转移和患者预后密切相关,它们的高表达提示预后不良。
Objective To observe the expression of tumor stem cell markers CD133 and CD147 in non-small cell lung cancer (NSCLC) tissues and their clinical significance. Methods The expression of CD133 and CD147 in 77 NSCLC tissues was detected by immunohistochemistry. The relationship between the expression of CD133 and CD147 in tumor size, histological type, histological differentiation, lymph node metastasis and prognosis was analyzed. Results The positive rates of CD133 and CD147 in 77 NSCLC tissues were 51.9% (40/77) and 67.5% (52/77), respectively. The expressions of CD133 and CD147 were positively correlated with the lymph node metastasis (r = 0.246, P <0.05; r = 0.295, P <0.05). The expressions of CD133 and CD147 were negatively correlated with the postoperative survival time (P <0.05). The expression of CD133 and CD147 had no significant correlation with tumor size, histological type and histological differentiation (P> 0.05). There was a positive correlation between the expression of CD133 and CD147 (r = 0.315, P <0.05). Conclusion The expression of tumor stem cell markers CD133 and CD147 are closely related to lymph node metastasis and prognosis of patients with NSCLC. Their high expression suggests poor prognosis.